

CLAIMS:

1. An isolated polypeptide comprising a sequence selected from the group consisting of sequences provided in SEQ ID NO: 11-20.
2. An isolated polypeptide comprising a sequence selected from the group consisting of:
 - (a) sequences having at least 40% identical residues to a sequence provided in SEQ ID NO: 11-20 as determined using the computer algorithm BLASTP;
 - (b) sequences having at least 60% identical residues to a sequence provided in SEQ ID NO: 11-20 as determined using the computer algorithm BLASTP;
 - (c) sequences having at least 75% identical residues to a sequence provided in SEQ ID NO: 11-20 as determined using the computer algorithm BLASTP; and
 - (d) sequences having at least 90% identical residues to a sequence provided in SEQ ID NO: 11-20 as determined using the computer algorithm BLASTP.
3. An isolated polynucleotide that encodes a polypeptide according to any one of claims 1 and 2.
4. An isolated polynucleotide comprising a sequence selected from the group consisting of sequences provided in SEQ ID NO: 1-10.
5. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) complements of the sequence recited in SEQ ID NO: 1-10;
 - (b) reverse complements of the sequence recited in SEQ ID NO: 1-10;
 - (c) reverse sequences of the sequences recited in SEQ ID NO: 1-10;
 - (d) sequences having at least 40% identical nucleotides to a sequence provided in SEQ ID NO: 1-10 as determined using the computer algorithm BLASTN;
 - (e) sequences having at least 60% identical nucleotides to a sequence provided in SEQ ID NO: 1-10 as determined using the computer algorithm BLASTN;
 - (f) sequences having at least 75% identical nucleotides to a sequence provided in SEQ ID NO: 1-10 as determined using the computer algorithm BLASTN; and
 - (g) sequences having at least 90% identical nucleotides to a sequence provided in SEQ ID NO: 1-10 as determined using the computer algorithm BLASTN.

6. An isolated polynucleotide comprising a sequence selected from the group consisting of: (a) sequences that are a 200-mer of an isolated polynucleotide according to any one of claims 1, 2 and 5; (b) sequences that are a 100-mer of an isolated polynucleotide according to any one of claims 1, 2 and 5; and (c) sequences that are a 40-mer of an isolated polynucleotide according to any one of claims 1, 2 and 5.
7. An expression vector comprising an isolated polynucleotide according to any one of claims 3-6.
8. A host cell transformed with an expression vector according to claim 7.
9. An isolated polypeptide comprising at least a functional portion of a polypeptide having an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO: 11-20.
10. A pharmaceutical composition comprising an isolated polypeptide according to any one of claims 1 and 2.
11. A pharmaceutical composition comprising an isolated polynucleotide according to any one of claims 3-6.
12. A method for the treatment of an inflammatory disorder in a patient, comprising administering to the patient a composition comprising an isolated polypeptide according to any one of claims 1 and 2.
13. A method for modulating the growth of blood vessels in a patient, comprising administering to the patient a composition comprising an isolated polypeptide according to any one of claims 1 and 2.
14. A method for the treatment of an disorder of the immune system in patient, comprising administering to the patient a composition comprising an isolated polypeptide according to any one of claims 1 and 2.
15. A method for the treatment of cancer in a patient, comprising administering to the patient a composition comprising an isolated polypeptide according to any one of claims 1 and 2, wherein the cancer is selected from the group consisting of epithelial, lymphoid, myeloid, stromal and neuronal cancers.
16. A method for the treatment of a tumour necrosis factor-mediated disorder in a patient, comprising administering to the patient a composition comprising an

isolated polypeptide, the polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a sequence of SEQ ID NO: 13;
- (d) sequences having at least 40% identical residues to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP;
- (e) sequences having at least 60% identical residues to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP;
- (f) sequences having at least 75% identical residues to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP; and
- (d) sequences having at least 90% identical residues to the sequence of SEQ ID NO: 13 as determined using the computer algorithm BLASTP.

- 17. The method of claim 16, wherein the tumour necrosis factor-mediated disorder is selected from the group consisting of arthritis, inflammatory bowel disease and cardiac failure.
- 18. A method for the treatment of a viral disorder in a patient, comprising administering to the patient a composition comprising an isolated polypeptide according to any one of claims 1 and 2.
- 19. The method of claim 19, wherein the viral disorder is HIV-infection.